S0000 Selenium and Vitamin E in Preventing Prostate Cancer

ClinicalTrials.gov ID: NCT00006392

Public ClinicalTrials.gov record NCT00006392. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be more effective in preventing prostate cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of selenium and vitamin E, either alone or together, in preventing prostate cancer.

Study identification

NCT ID: NCT00006392
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: SWOG Cancer Research Network; Network
Enrollment: 35,533 participants

Conditions and interventions

Conditions

Prostate Cancer

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 50 Years to 120 Years
Sex: Male
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 2001 (Type not available)
Primary completion: May 2011 (Actual)
Completion: Sep 2012 (Actual)
Last update posted: Nov 20, 2015

2001 – 2012

United States locations

U.S. sites: 13
U.S. states: 6
U.S. cities: 11

Facility	City	State	ZIP	Site status
Robert H. Lurie Comprehensive Cancer Center at Northwestern University	Chicago	Illinois	60611-3013	—
Midwest Center for Hematology/Oncology	Joliet	Illinois	60432	—
Cardinal Bernardin Cancer Center at Loyola University Medical Center	Maywood	Illinois	60153	—
CCOP - Cancer Research for the Ozarks	Springfield	Missouri	65802	—
St. John's Regional Health Center	Springfield	Missouri	65804	—
Good Samaritan Hospital Cancer Treatment Center	Cincinnati	Ohio	45220	—
Bethesda North Hospital	Cincinnati	Ohio	45242	—
Tod Children's Hospital	Youngstown	Ohio	44501	—
LaFortune Cancer Center at St. John Medical Center	Tulsa	Oklahoma	74104	—
Geisinger Medical Center	Danville	Pennsylvania	17822-0001	—
Geisinger Medical Group - Scenery Park	State College	Pennsylvania	16801	—
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center	Wilkes-Barre	Pennsylvania	18711	—
U.T. Cancer Institute at University of Tennessee Medical Center	Knoxville	Tennessee	37920-6999	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00006392, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 20, 2015 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00006392 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →